Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis.
Patients with different forms of multiple sclerosis were treated with a vaccine consisting of myelin-reactive T cells. It was found that after this treatment, lymphocytes from patients acquired the capacity to generate antiidiotypic proliferative response directed towards myelin-reactive T cells. The serum concentration of IFN-gamma decreased about 2-fold 1.5-2.0 years after the start of vaccine therapy, whereas the concentration of IL-4 increased 2-3 fold. Myelin-reactive proliferative activity of peripheral blood mononuclear cells also decreased. The results of the 2-year follow-up study revealed no side effect of T-cell vaccination in patients with cerebrospinal form of multiple sclerosis and demonstrated its possible clinical efficiency in the treatment of this disease at early stages.
Ivanova
I P
IP
Research Institute of Clinical Immunology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk, Russia. irinaiki@rambler.ru
Seledtsov
V I
VI
Seledtsova
G V
GV
Mamaev
S V
SV
Potyemkin
A V
AV
Seledtsov
D V
DV
Kozlov
V A
VA
D000293:Adolescent; D000328:Adult; D049109:Cell Proliferation; D006801:Humans; D055633:Immune System Phenomena; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D015847:Interleukin-4 / Q000097:blood / Q000276:immunology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy; D009186:Myelin Sheath / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014612:Vaccines / Q000276:immunology / Q000627:therapeutic use; D055815:Young Adult
D014612:Vaccines; D015847:Interleukin-4; D007371:Interferon-gamma